Selexipag Triple Therapy Outcomes in Chinese PAH Patients, 2022-2023

Xiaopei Cui's retrospective study from Qilu Hospital of Shandong University includes safety and efficacy data for 153 Chinese patients with pulmonary arterial hypertension treated with selexipag-based triple therapy between February 2022 and November 2023. The dataset likely contains clinical parameters such as WHO functional class, 6-minute walk distance, NT-proBNP levels, echocardiogram results, and non-invasive risk assessment scores. It was last updated on 2026-05-21 and is shared under a CC-BY-4.0 license.

Use Cases

• Compare initial versus sequential triple therapy efficacy based on hazard ratios for disease progression.
• Analyze changes in right heart structure and function based on echocardiogram parameters like right atrial area and tricuspid annular plane systolic excursion.
• Model improvements in exercise capacity based on 6-minute walk distance measurements before and after treatment.
• Assess shifts in patient risk stratification based on the count of low-risk criteria met over a follow-up period.

Strengths

• Includes data for 153 patients in safety analysis and 146 in efficacy analysis, providing a defined cohort size.
• Reports specific clinical outcomes, such as 65.8% of patients reaching WHO FC II after a median 29 weeks of treatment.
• Contains a follow-up period averaging 33 ± 10 months, offering longitudinal insight.
• Provides a concrete hazard ratio (0.177) comparing initial and sequential therapy strategies.

Limitations

• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

Qilu Hospital of Shandong University

Collection Method

Single-center, retrospective study.

Time Range

February 2022 to November 2023, with an average follow-up of 33 months.

Freshness

Last updated 2026-05-21 05:44:05; freshness should be verified.

Geography

China